The promise of affordable biologic medications – life-altering drugs for conditions like cancer, rheumatoid arthritis, and diabetes – is facing a critical bottleneck. While a wave of patent expirations over the next decade should usher in an era of cheaper “biosimilar” alternatives, a surprisingly small percentage of these drugs are actually seeing follow-on competition. This isn’t simply a matter of waiting for market forces to correct; it reveals a complex interplay of economic incentives, regulatory hurdles, and evolving treatment landscapes that are actively shaping who benefits from pharmaceutical innovation. The narrative often focuses on the potential cost savings, but a closer look reveals a system where the most profitable drugs are prioritized for biosimilar development, potentially leaving patients reliant on expensive therapies for less commercially attractive conditions.
Since 2015, the Food and Drug Administration has approved over 90 biosimilars, with nearly 25 more anticipated in the next two years, spanning oncology, immunology, and retinal disease treatments, according to a recent report by Cardinal Health, a $53 billion healthcare distributor. This influx has already generated over $56 billion in cost savings. The upcoming wave is particularly significant: in 2026 alone, biosimilars are expected for widely used drugs like Janssen’s Simponi, Eli Lilly’s Humalog, Genentech’s Xolair, and even AbbVie’s Botox. However, these successes represent only a fraction of the opportunity. Cardinal Health estimates that only 10% of the 110+ biologics losing patent protection in the next ten years currently have biosimilar development underway. This gap isn’t accidental.
Fran Gregory, VP of emerging therapies at Cardinal Health, succinctly explains the driving force: “There are some types of products that are very attractive for biosimilar development, and some don’t make as much sense.” The case of Humira, the blockbuster arthritis drug, serves as a prime example. Its patent expiration in 2023 triggered a surge of biosimilar competition and substantial cost reductions. However, as highlighted in a report by the life sciences analytics firm Iqvia, biosimilar developers overwhelmingly target medicines with over $1 billion in annual sales. While this strategy maximizes potential return on investment, it overlooks the cumulative impact of smaller-market drugs – those generating $500 million or $700 million in revenue – on overall healthcare expenditure and patient access. The focus on blockbuster drugs isn’t necessarily a malicious act, but a rational economic decision within the current pharmaceutical framework.
Based on the original Forbes report.
The development of biosimilars is inherently more complex and costly than that of traditional generic drugs. Biosimilars are not identical copies; they are highly similar, requiring extensive clinical trials to demonstrate comparable safety and efficacy. These trials, coupled with the specialized manufacturing processes, translate to significantly higher development costs and longer timelines. Recognizing this, the FDA announced draft guidance in October 2025 aimed at streamlining the approval process, potentially reducing development costs by as much as $100 million and accelerating time to market. This is a crucial step, but it doesn’t address the underlying economic disincentives for pursuing biosimilars for less profitable drugs.
Furthermore, the opaque nature of pharmaceutical pricing complicates the picture. Negotiated prices between insurance companies, pharmacy benefit managers, and manufacturers, along with confidential rebate agreements, obscure the true cost of medications. Even when a biosimilar reaches the market, the price gap with the original biologic may be smaller than anticipated, as the brand-name drug’s price often declines upon patent expiration. A recent Cardinal Health survey revealed that 26% of physician practices are “very concerned” that biosimilar costs will eventually exceed reimbursement rates for the original medication, while 56% expressed “some concern.” This apprehension, while not preventing biosimilar prescriptions, highlights the need for greater transparency and predictable pricing models.
Interestingly, physician comfort levels with prescribing and explaining biosimilars to patients are increasing. Cardinal Health’s survey found that 99% of practices are now comfortable discussing biosimilars with their patients – a dramatic shift from just five years ago. This suggests that education and awareness initiatives are proving effective, but they are only one piece of the puzzle. The current trajectory suggests a future where biosimilar competition primarily benefits patients using high-cost, blockbuster drugs, while those relying on less profitable biologics may continue to face significant financial burdens.
Looking ahead, the critical question isn’t simply if more biosimilars will be developed, but which biologics will receive that investment. Will regulatory streamlining and increased transparency be enough to incentivize developers to pursue biosimilars for a wider range of drugs, or will the market continue to prioritize profitability over equitable access? Patients and healthcare providers should actively monitor which biosimilar development programs are announced in the coming years, paying particular attention to drugs treating conditions beyond the most common and lucrative disease states. The answer will reveal whether the promise of affordable biologics will truly reach all who need them.
